PHIA Stock Analysis: Koninklijke Philips | AS
Medical Devices | AS, Netherlands | Market Cap: 21.073m EUR | 12M Return: -7% | NL0000009538 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 32.5M
EPS Trend: 47.7%
Qual. Beats: 1
Rev. Trend: -95.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Koninklijke Philips N.V. (PHIA) is a Netherlands-based health technology company headquartered in Amsterdam, operating across North America, Greater China, and other international markets. Founded in 1891 and renamed from Koninklijke Philips Electronics N.V. in May 2013, the company has shifted its focus from consumer electronics to healthcare technology.
Philips operates through three business segments: Diagnosis & Treatment (which includes diagnostic imaging such as ultrasound, MRI, CT, and X-ray, as well as image-guided therapy systems and devices), Connected Care (covering patient monitoring, enterprise informatics, and sleep and respiratory care), and Personal Health. The company also maintains a strategic alliance with WellSpan Health focused on advanced imaging and diagnostics technology.
As a player in the Health Care Equipment sub-industry, Philips operates in a sector characterized by long product development cycles, stringent regulatory requirements, and demand driven by hospital capital expenditure, aging populations, and the global shift toward value-based care. Its diversified portfolio spanning clinical-grade equipment, connected health solutions, and consumer wellness products positions it across both institutional healthcare providers and retail consumers.
- CPAP recall lawsuits and FDA consent decree pressure margins
- Greater China revenue declines amid hospital spending slowdown
- Imaging segment orders rebound as hospital capex recovers
| Net Income: 1.11b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 5.46 > 1.0 |
| NWC/Revenue: 10.80% < 20% (prev 10.43%; Δ 0.37% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.28b > Net Income 1.11b |
| Net Debt (6.64b) to EBITDA (3.06b): 2.17 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (968.6m) vs 12m ago 1.24% < -2% |
| Gross Margin: 45.93% > 18% (prev 43.85%; Δ 2.08% > 0.5%) |
| Asset Turnover: 66.56% > 50% (prev 67.69%; Δ -1.13% > 0%) |
| Interest Coverage Ratio: 5.32 > 6 (EBIT TTM 1.83b / Interest Expense TTM 344.0m) |
| A: 0.07 (Total Current Assets 9.33b - Total Current Liabilities 7.42b) / Total Assets 26.7b |
| B: 0.12 (Retained Earnings 3.18b / Total Assets 26.7b) |
| C: 0.07 (EBIT TTM 1.83b / Avg Total Assets 26.5b) |
| D: 0.75 (Book Value of Equity 11.4b / Total Liabilities 15.2b) |
| Altman-Z'' = 2.11 = BBB |
| DSRI: 1.09 (Receivables 3.60b/3.33b, Revenue 17.7b/17.9b) |
| GMI: 0.95 (GM 43.85% / 45.93%) |
| AQI: 1.00 (AQ_t 0.57 / AQ_t-1 0.57) |
| SGI: 0.99 (Revenue 17.7b / 17.9b) |
| TATA: -0.04 (NI 1.11b - CFO 2.28b) / TA 26.7b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at EUR 21.78 with a total of 1,951,296 shares traded. Over the past week, the price has changed by +2.40%, over one month by +0.55%, over three months by -8.95% and over the past year by -6.99%.
Current recommended Stop Loss: 21.00 (which is 3.6% or 2 ATR below the current price).
Koninklijke Philips has no consensus analysts rating.
P/E Trailing = 18.7478
P/E Forward = 12.6422
P/S = 1.1929
P/B = 1.8469
P/EG = 0.7529
Revenue TTM = 17.7b EUR
EBIT TTM = 1.83b EUR
EBITDA TTM = 3.06b EUR
Long Term Debt = 6.32b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortTermDebt, last quarter)
Debt = 8.43b EUR (from shortLongTermDebtTotal, last quarter) + Leases 964.0m
Net Debt = 6.64b EUR (calculated: Debt 8.43b - CCE 1.79b)
Enterprise Value = 27.7b EUR (21.1b + Debt 8.43b - CCE 1.79b)
Interest Coverage Ratio = 5.32 (Ebit TTM 1.83b / Interest Expense TTM 344.0m)
EV/FCF = 14.58x (Enterprise Value 27.7b / FCF TTM 1.90b)
FCF Yield = 6.86% (FCF TTM 1.90b / Enterprise Value 27.7b)
FCF Margin = 10.76% (FCF TTM 1.90b / Revenue TTM 17.7b)
Net Margin = 6.31% (Net Income TTM 1.11b / Revenue TTM 17.7b)
Gross Margin = 45.93% ((Revenue TTM 17.7b - Cost of Revenue TTM 9.55b) / Revenue TTM)
Gross Margin QoQ = 49.31% (prev 45.20%)
Tobins Q-Ratio = 1.04 (Enterprise Value 27.7b / Total Assets 26.7b)
Interest Expense / Debt = 4.08% (Interest Expense 344.0m / Debt 8.43b)
Taxrate = 24.64% (364.0m / 1.48b)
NOPAT = 1.38b (EBIT 1.83b * (1 - 24.64%))
Current Ratio = 1.26 (Total Current Assets 9.33b / Total Current Liabilities 7.42b)
Debt / Equity = 0.74 (Debt 8.43b / totalStockholderEquity, last quarter 11.4b)
Debt / EBITDA = 2.17 (Net Debt 6.64b / EBITDA 3.06b)
Debt / FCF = 3.49 (Net Debt 6.64b / FCF TTM 1.90b)
Total Stockholder Equity = 11.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.20% (Net Income 1.11b / Total Assets 26.7b)
RoE = 10.05% (Net Income TTM 1.11b / Total Stockholder Equity 11.1b)
RoCE = 10.51% (EBIT 1.83b / Capital Employed (Equity 11.1b + L.T.Debt 6.32b))
RoIC = 7.05% (NOPAT 1.38b / Invested Capital 19.5b)
WACC = 6.45% (E(21.1b)/V(29.5b) * Re(7.80%) + D(8.43b)/V(29.5b) * Rd(4.08%) * (1-Tc(0.25)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.94 | Cagr: 1.95%
[DCF] Terminal Value 77.97% ; FCFF base≈1.32b ; Y1≈1.51b ; Y5≈2.22b
[DCF] Fair Price = 27.39 (EV 33.4b - Net Debt 6.64b = Equity 26.8b / Shares 977.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 47.74 | EPS CAGR: 152.6% | SUE: 1.74 | # QB: 1
Revenue Correlation: -95.13 | Revenue CAGR: -1.45% | SUE: 0.49 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.34 | Chg30d=-0.32% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=1.64 | Chg30d=+0.46% | Revisions=+72% | GrowthEPS=+5.1% | GrowthRev=+0.5%
EPS next Year (2027-12-31): EPS=1.68 | Chg30d=-0.01% | Revisions=-35% | GrowthEPS=+2.6% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: +11% (up=18, down=14)